Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
08:30am, Monday, 04'th Mar 2024
COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Bi
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?
01:00pm, Thursday, 15'th Feb 2024
Does Ascendis Pharma A/S (ASND) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
10:40am, Thursday, 15'th Feb 2024
Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript
10:18pm, Wednesday, 07'th Feb 2024
Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
04:01pm, Wednesday, 07'th Feb 2024
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08:30am, Wednesday, 07'th Feb 2024
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Scienc
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
09:51am, Tuesday, 06'th Feb 2024
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
04:15pm, Wednesday, 31'st Jan 2024
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, Fe
Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript
08:22pm, Tuesday, 07'th Nov 2023
Ascendis Pharma A/S (ASND) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Timothy Lee - Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott
Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission
08:30am, Tuesday, 31'st Oct 2023
• Third Quarter financial results and business update conference call to be held on November 7, 2023 • Resubmission of TransCon PTH NDA for adults with hypoparathyroidism expected before mid-Novem
Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:23am, Thursday, 26'th Oct 2023
The heavy selling pressure might have exhausted for Ascendis Pharma A/S (ASND) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?
09:01am, Friday, 15'th Sep 2023
Ascendis Pharma A/S (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near t
Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript
07:43pm, Tuesday, 05'th Sep 2023
Ascendis Pharma A/S (ASND) Q2 2023 Earnings Conference Call September 5, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executiv
Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023
08:30am, Tuesday, 15'th Aug 2023
COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday,
How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35%
11:30am, Thursday, 10'th Aug 2023
The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
